Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Blood

Volumn 99, Issue 12, 2002, Pages 4364-4369

  Van Esser, Joost W J ^a,b   Niesters, Hubert G M ^a,b   Van Der Holt, Bronno ^a,b   Meijer, Ellen ^a,b   Osterhaus, Albert D M E ^a,b   Gratama, Jan Willem ^a,b   Verdonck, Leo F ^a,b   Löwenberg, Bob ^a,b   Cornelissen, Jan J ^a,b,c  

^a STATISTICS NETHERLANDS   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INFUSION; EPSTEIN BARR VIRUS; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION PREVENTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MORTALITY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; VIRUS REACTIVATION;

EID: 0037097731     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.12.4364     Document Type: Article

References (35)

1. Cytomegalovirus: The taming of the beast?
2. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation: Current guidelines and future prospects
3. Cytomegalovirus after BMT
4. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease
5. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of post-transplant lymphoproliferative disease in high-risk patients
6. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation
7. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease
8. Development of a real-time quantitative assay for detection of Epstein-Barr virus
9. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus associated lymphoproliferative disease after allogeneic stem cell transplantation
10. Epstein-Barr virus (EBV) reactivation is a very frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell depleted SCT
11. B cell lymphoproliferative disorders following hematopoetic stem cell transplantation: Risk factors, treatment and outcome
12. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
13. Biology and adoptive cell therapy of Epstein-Barr virus associated lymphoproliferative disorders in recipients of marrow allografts
14. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
15. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
16. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
17. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children
18. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation
19. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders
20. Allogeneic bone marrow transplantation with a fixed low number of T-cells in the marrow graft
21. Nonparametric estimation for incomplete observations
22. Evaluation of survival data and two new rank order statistics arising in its consideration
23. Infusions of donor lymphocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
24. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
25. Epstein-Barr (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: Prophylactic infusion of EBV-specific cytotoxic T cells
26. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs
27. Viral subversion of the immune system
28. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression
29. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study
30. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response
31. The antiviral prophylaxis of post-transplant lymphoproliferative disorder
32. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lympoproliferative lesions: The role of primary infection
33. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases
34. Identification of Epstein-Barr virus lytic activity in post-transplantation lymphoproliferative disease
35. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man